Achieve Life Sciences (ACHV) Other Non Operating Income (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Other Non Operating Income came in at -$13000.0 in Q1 2026, down 161.9% YoY from $21000.0 in Q1 2025, and down 285.71% on a QoQ basis from $7000.0 in Q4 2025.
Powered by 
Analysis
Achieve Life Sciences (ACHV) Other Non Operating Income (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Other Non Operating Income data on file, last reported at -$13000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 161.9% year-over-year to -$13000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$70000.0 (up 71.66% YoY) and the FY2025 annual result came in at -$36000.0, up 87.28% from the prior year.
- Other Non Operating Income retreated to -$13000.0 in Q1 2026, from $7000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $59000.0 in Q4 2022 to a low of -$258000.0 in Q4 2024.
- A 5-year average of -$17705.9 and a median of -$5000.0 in 2025 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 251.28% in 2022, down 2900.0% in 2022.
- Tracing ACHV's Other Non Operating Income over 5 years: stood at $59000.0 in 2022, then tumbled by 71.19% to $17000.0 in 2023, then plunged by 1617.65% to -$258000.0 in 2024, then surged by 102.71% to $7000.0 in 2025, then sank by 285.71% to -$13000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$13000.0 (Q1 2026), $7000.0 (Q4 2025), and -$5000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.80 Bn | 130.95 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.54 Bn | 77.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.40 Bn | 32.09 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Achieve Life Sciences | 370.34 Mn | 370.34 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -144,000.00 |
| Mar 31, 2026 | -13,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Jun 30, 2025 | -59,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Sep 30, 2024 | -283,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | -17,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | -30,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | -39,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -12,000.00 |